Weight-loss drug developer BioAge raises $198 mln in U.S. IPO
WEB2 days ago · BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on Wednesday.
BioAge stock rallies 29% following upsized $198M IPO
WEB2 days ago · Shares of BioAge (BIOA) recently sold for $23.30, up 29% from its offering price, at around 12:20 p.m. ET. BioAge (BIOA) priced 11M shares at $18 per share. Underwriters were granted a 30-day ...
BioAge Labs Announces Pricing of Upsized Initial Public Offering
WEB3 days ago · Advertisement. RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product ...
BioAge Labs IPO: stock price today in high-profile Nasdaq debut
WEB3 days ago · How many BioAge shares are available in its IPO? BioAge is offering 11 million shares of its common stock in the IPO. All the shares are being offered by BioAge itself. ... News NASA SpaceX Crew-9 ...
BioAge prices $198M IPO, validating pivot to obesity drug research
WEB4 days ago · BioAge, which is evaluating a medicine that’s meant to boost the effects of popular obesity drugs known as GLP-1 agonists, sold 11 million shares at $18 apiece in the offering. Those numbers exceed projections set by the company last week, and were accrued shortly after the company had already hiked the size of its offering by 40%.
Obesity drug developer BioAge raises $198m in IPO
WEB3 days ago · BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%. The expansion of the listing reflects the massive ...
Obesity drug developer BioAge Labs aims up to $640 mln …
WEB3 days ago · BioAge now offering 10.5 mln shares, vs 7.5 mln earlier Sofinnova expected to invest up to $1.4 mln in IPO Investment firm expected to buy shares worth $10.6 mln in private placement Sept 25 ...
BioAge Labs Files For $100M IPO, Becomes The New Entrant In …
WEBSep 4, 2024 · BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering.
Weight loss drug maker BioAge Labs eyes $200 million IPO - Quartz
WEB3 days ago · The Richmond, California-based company said on Wednesday that it plans to offer 10.5 million shares between $17 and $19 each. BioAge previously planned to only offer 7.5 million shares at the same ...
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
WEBSep 18, 2024 · Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory...
- Some results have been removed
Skip to content